209 related articles for article (PubMed ID: 37380578)
21. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
22. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Azad AA; Tran B; Davis ID; Parente P; Evans M; Wong S; Brown S; Evans S; Millar J; Murphy DG; Papa N
Intern Med J; 2022 Aug; 52(8):1339-1346. PubMed ID: 33710759
[TBL] [Abstract][Full Text] [Related]
23. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.
Gupta N; Gupta D; Vaska KG; Prinja S
Appl Health Econ Health Policy; 2024 May; 22(3):415-426. PubMed ID: 38198103
[TBL] [Abstract][Full Text] [Related]
27. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Ozaki K; Hatakeyama S; Narita S; Hata K; Yanagisawa T; Tanaka T; Togashi K; Hamaya T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Kimura T; Habuchi T; Ohyama C
World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204
[TBL] [Abstract][Full Text] [Related]
28. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
29. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
30. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
Omrčen T
Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
[TBL] [Abstract][Full Text] [Related]
32. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
33. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Lee A
Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
[TBL] [Abstract][Full Text] [Related]
34. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
Borque-Fernando A; Calleja-Hernández MA; Cózar-Olmo JM; Gómez-Iturriaga A; Pérez-Fentes DA; Puente-Vázquez J; Rodrigo-Aliaga M; Unda M; Álvarez-Ossorio JL
Actas Urol Esp (Engl Ed); 2023 Mar; 47(2):111-126. PubMed ID: 36720305
[TBL] [Abstract][Full Text] [Related]
35. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
[TBL] [Abstract][Full Text] [Related]
36. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study.
Storås AH; Tsuruda K; Fosså SD; Andreassen BK
Acta Oncol; 2023 Dec; 62(12):1716-1722. PubMed ID: 37725527
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
[TBL] [Abstract][Full Text] [Related]
38. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
[TBL] [Abstract][Full Text] [Related]
39. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]